JP6472572B2 - バルーンカテーテルおよびその製造方法並びに処置方法 - Google Patents
バルーンカテーテルおよびその製造方法並びに処置方法 Download PDFInfo
- Publication number
- JP6472572B2 JP6472572B2 JP2018507392A JP2018507392A JP6472572B2 JP 6472572 B2 JP6472572 B2 JP 6472572B2 JP 2018507392 A JP2018507392 A JP 2018507392A JP 2018507392 A JP2018507392 A JP 2018507392A JP 6472572 B2 JP6472572 B2 JP 6472572B2
- Authority
- JP
- Japan
- Prior art keywords
- balloon
- water
- base layer
- balloon catheter
- elongate body
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 19
- 238000004519 manufacturing process Methods 0.000 title claims description 15
- 239000003814 drug Substances 0.000 claims description 97
- 229940079593 drug Drugs 0.000 claims description 94
- 239000013078 crystal Substances 0.000 claims description 88
- 239000011248 coating agent Substances 0.000 claims description 43
- 238000000576 coating method Methods 0.000 claims description 43
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- -1 citrate ester Chemical class 0.000 claims description 25
- 150000003384 small molecules Chemical class 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 20
- 239000003960 organic solvent Substances 0.000 claims description 18
- 239000004952 Polyamide Substances 0.000 claims description 14
- 229920002647 polyamide Polymers 0.000 claims description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 229930012538 Paclitaxel Natural products 0.000 claims description 8
- 229960001592 paclitaxel Drugs 0.000 claims description 8
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 8
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 7
- 229960002930 sirolimus Drugs 0.000 claims description 7
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 7
- 230000008961 swelling Effects 0.000 claims description 7
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 6
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 6
- 229960003668 docetaxel Drugs 0.000 claims description 6
- 229960005167 everolimus Drugs 0.000 claims description 6
- GKCXXDSWWDWUHS-BYPYZUCNSA-N ethyl (2s)-2-amino-3-hydroxypropanoate Chemical compound CCOC(=O)[C@@H](N)CO GKCXXDSWWDWUHS-BYPYZUCNSA-N 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 claims description 4
- 229920000136 polysorbate Polymers 0.000 claims description 4
- 229950008882 polysorbate Drugs 0.000 claims description 4
- 239000010410 layer Substances 0.000 description 158
- 210000001519 tissue Anatomy 0.000 description 32
- 239000000243 solution Substances 0.000 description 29
- 239000000463 material Substances 0.000 description 18
- 230000007246 mechanism Effects 0.000 description 16
- 208000031481 Pathologic Constriction Diseases 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 239000007788 liquid Substances 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 230000036262 stenosis Effects 0.000 description 12
- 208000037804 stenosis Diseases 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 210000004204 blood vessel Anatomy 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 239000011247 coating layer Substances 0.000 description 10
- 229920001577 copolymer Polymers 0.000 description 10
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 6
- 229920001971 elastomer Polymers 0.000 description 6
- 239000000806 elastomer Substances 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 229920002292 Nylon 6 Polymers 0.000 description 5
- 229920000728 polyester Polymers 0.000 description 5
- 229920000571 Nylon 11 Polymers 0.000 description 4
- 238000005452 bending Methods 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 239000011162 core material Substances 0.000 description 4
- 229920000098 polyolefin Polymers 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920000299 Nylon 12 Polymers 0.000 description 3
- 229920002302 Nylon 6,6 Polymers 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 239000002872 contrast media Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 229920000573 polyethylene Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 229920002635 polyurethane Polymers 0.000 description 3
- 239000004814 polyurethane Substances 0.000 description 3
- 229920012753 Ethylene Ionomers Polymers 0.000 description 2
- JHWNWJKBPDFINM-UHFFFAOYSA-N Laurolactam Chemical compound O=C1CCCCCCCCCCCN1 JHWNWJKBPDFINM-UHFFFAOYSA-N 0.000 description 2
- 229920000305 Nylon 6,10 Polymers 0.000 description 2
- 229920000572 Nylon 6/12 Polymers 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 229930182912 cyclosporin Natural products 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920001083 polybutene Polymers 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229920002379 silicone rubber Polymers 0.000 description 2
- 239000004945 silicone rubber Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 2
- 229920005992 thermoplastic resin Polymers 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- GVNWZKBFMFUVNX-UHFFFAOYSA-N Adipamide Chemical compound NC(=O)CCCCC(N)=O GVNWZKBFMFUVNX-UHFFFAOYSA-N 0.000 description 1
- GDOPTJXRTPNYNR-UHFFFAOYSA-N CC1CCCC1 Chemical compound CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229920003189 Nylon 4,6 Polymers 0.000 description 1
- 229920000577 Nylon 6/66 Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 229920003232 aliphatic polyester Polymers 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 239000004760 aramid Substances 0.000 description 1
- 229920003235 aromatic polyamide Polymers 0.000 description 1
- TZYHIGCKINZLPD-UHFFFAOYSA-N azepan-2-one;hexane-1,6-diamine;hexanedioic acid Chemical compound NCCCCCCN.O=C1CCCCCN1.OC(=O)CCCCC(O)=O TZYHIGCKINZLPD-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- ILRSCQWREDREME-UHFFFAOYSA-N dodecanamide Chemical compound CCCCCCCCCCCC(N)=O ILRSCQWREDREME-UHFFFAOYSA-N 0.000 description 1
- ZMUCVNSKULGPQG-UHFFFAOYSA-N dodecanedioic acid;hexane-1,6-diamine Chemical compound NCCCCCCN.OC(=O)CCCCCCCCCCC(O)=O ZMUCVNSKULGPQG-UHFFFAOYSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229920001038 ethylene copolymer Polymers 0.000 description 1
- 229920000840 ethylene tetrafluoroethylene copolymer Polymers 0.000 description 1
- XUCNUKMRBVNAPB-UHFFFAOYSA-N fluoroethene Chemical group FC=C XUCNUKMRBVNAPB-UHFFFAOYSA-N 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 239000002698 neuron blocking agent Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000009751 slip forming Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
- A61M25/0023—Catheters; Hollow probes characterised by the form of the tubing by the form of the lumen, e.g. cross-section, variable diameter
- A61M25/0026—Multi-lumen catheters with stationary elements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1027—Making of balloon catheters
- A61M25/1029—Production methods of the balloon members, e.g. blow-moulding, extruding, deposition or by wrapping a plurality of layers of balloon material around a mandril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/104—Balloon catheters used for angioplasty
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D1/00—Processes for applying liquids or other fluent materials
- B05D1/002—Processes for applying liquids or other fluent materials the substrate being rotated
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D1/00—Processes for applying liquids or other fluent materials
- B05D1/26—Processes for applying liquids or other fluent materials performed by applying the liquid or other fluent material from an outlet device in contact with, or almost in contact with, the surface
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D1/00—Processes for applying liquids or other fluent materials
- B05D1/40—Distributing applied liquids or other fluent materials by members moving relatively to surface
- B05D1/42—Distributing applied liquids or other fluent materials by members moving relatively to surface by non-rotary members
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/54—Organic compounds
- C30B29/58—Macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/60—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape characterised by shape
- C30B29/62—Whiskers or needles
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- C30B7/02—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent
- C30B7/06—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by evaporation of the solvent using non-aqueous solvents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0021—Catheters; Hollow probes characterised by the form of the tubing
- A61M25/0023—Catheters; Hollow probes characterised by the form of the tubing by the form of the lumen, e.g. cross-section, variable diameter
- A61M25/0026—Multi-lumen catheters with stationary elements
- A61M2025/0039—Multi-lumen catheters with stationary elements characterized by lumina being arranged coaxially
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1027—Making of balloon catheters
- A61M25/1029—Production methods of the balloon members, e.g. blow-moulding, extruding, deposition or by wrapping a plurality of layers of balloon material around a mandril
- A61M2025/1031—Surface processing of balloon members, e.g. coating or deposition; Mounting additional parts onto the balloon member's surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1061—Balloon catheters with special features or adapted for special applications having separate inflations tubes, e.g. coaxial tubes or tubes otherwise arranged apart from the catheter tube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1075—Balloon catheters with special features or adapted for special applications having a balloon composed of several layers, e.g. by coating or embedding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/1086—Balloon catheters with special features or adapted for special applications having a special balloon surface topography, e.g. pores, protuberances, spikes or grooves
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
- B05D2401/00—Form of the coating product, e.g. solution, water dispersion, powders or the like
- B05D2401/20—Aqueous dispersion or solution
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials Engineering (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Metallurgy (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Manufacturing & Machinery (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
前記長尺体は、基端部が前記バルーンの外表面から離れ、かつ前記基層の内部に位置する第1の長尺体を有してもよい。これにより、第1の長尺体の基端部の位置を基層の内部で調節することで、水溶性低分子化合物を含む基層が溶ける時間を利用して、薬剤の生体組織への送達性を調節できる。
前記バルーンは、ポリアミド類により形成されてもよい。
前記基層に含まれる前記水溶性低分子化合物は、結晶、アモルファス、またはこれらの混合物であってもよい。
前記水不溶性薬剤は、ラパマイシン、パクリタキセル、ドセタキセル、またはエベロリムスであってもよい。これにより、少なくとも一部が基層の内部に位置する長尺体により、血管内の狭窄部の再狭窄を良好に抑制できる。
前記基層は、表面に凹凸を有してもよい。
前記バルーンの外表面は、前記長尺体が設けられない領域の少なくとも一部に、前記基層に覆われずに外部へ露出する部位を有してもよい。
隣接する前記長尺体同士は、構造的に離れていてもよい。
複数の前記長尺体のうちの一部の隣接する前記長尺体同士は、接触していてもよい。
20 カテーテル本体、
21 外管、
22 内管、
30 バルーン、
40 コート層、
41 基層、
42 長尺体、
42A 第1の長尺体、
42B 第2の長尺体、
42C 第3の長尺体、
46 固定側長尺体(バルーン基材接触結晶粒子)、
47 分離側長尺体(バルーン基材接触結晶粒子)、
50 バルーンコーティング装置、
94 ディスペンシングチューブ。
Claims (17)
- 独立した長軸を有して延在する水不溶性薬剤の結晶である複数の長尺体がバルーンの外表面に設けられるバルーンカテーテルであって、
バルーンの外表面に層状に配置され、分子量が50〜2000であって5mg/mL以上水に溶け、膨潤せずに水に溶解する水溶性低分子化合物を含む基層を有し、
前記長尺体の少なくとも一部は、前記基層の内部に位置し、
前記長尺体は、基端部が前記バルーンの平滑で非多孔質の外表面から離れ、かつ前記基層の内部に位置する第1の長尺体を有するバルーンカテーテル。 - 前記長尺体は、前記バルーンの外表面から延在する第2の長尺体および/または前記基層の外表面から面外方向へ延在する第3の長尺体を有する請求項1に記載のバルーンカテーテル。
- 独立した長軸を有して延在する水不溶性薬剤の結晶である複数の長尺体がバルーンの外表面に設けられるバルーンカテーテルであって、
バルーンの外表面に層状に配置され、分子量が50〜2000であって5mg/mL以上水に溶け、膨潤せずに水に溶解する水溶性低分子化合物を含む基層を有し、
前記長尺体の少なくとも一部は、前記基層の内部に位置し、
前記長尺体は、前記バルーンの平滑で非多孔質の外表面から延在する第2の長尺体を有するバルーンカテーテル。 - 前記長尺体は、基端部が前記バルーンの外表面から離れ、かつ前記基層の内部に位置する第1の長尺体および/または前記基層の外表面から面外方向へ延在する第3の長尺体を有する請求項3に記載のバルーンカテーテル。
- 前記水溶性低分子化合物は、セリンエチルエステル、クエン酸エステル、ポリソルベート、糖、アミノ酸エステル、または短鎖モノカルボン酸のグリセロールエステルの少なくとも1つである請求項1〜4のいずれか1項に記載のバルーンカテーテル。
- 前記バルーンは、ポリアミド類により形成される請求項1〜5のいずれか1項に記載のバルーンカテーテル。
- 前記基層に含まれる前記水溶性低分子化合物は、結晶、アモルファス、またはこれらの混合物である請求項1〜6のいずれか1項に記載のバルーンカテーテル。
- 前記水不溶性薬剤は、ラパマイシン、パクリタキセル、ドセタキセル、またはエベロリムスである請求項1〜7のいずれか1項に記載のバルーンカテーテル。
- 前記基層は、表面に凹凸を有する請求項1〜8のいずれか1項に記載のバルーンカテーテル。
- 前記バルーンの外表面は、前記長尺体が設けられない領域の少なくとも一部に、前記基層に覆われずに外部へ露出する部位を有する請求項1〜9のいずれか1項に記載のバルーンカテーテル。
- 隣接する前記長尺体同士は、構造的に離れている請求項1〜10のいずれか1項に記載のバルーンカテーテル。
- 複数の前記長尺体のうちの一部の隣接する前記長尺体同士は、接触している請求項1〜10のいずれか1項に記載のバルーンカテーテル。
- 独立した長軸を有して延在する水不溶性薬剤の結晶である複数の長尺体がバルーンの外表面に設けられるバルーンカテーテルの製造方法であって、
薬剤、分子量が50〜2000であって5mg/mL以上水に溶け、膨潤せずに水に溶解する水溶性低分子化合物、有機溶媒および水を含むコーティング溶液を供給するディスペンシングチューブを前記バルーンの平滑で非多孔質の外表面に接触させつつ当該ディスペンシングチューブから前記コーティング溶液を供給し、物理的な刺激を与えることで前記水不溶性薬剤の結晶核を形成するステップと、
水を残しつつ有機溶媒を揮発させて前記結晶核を基に前記長尺体を成長させるステップと、
水を蒸発させて水溶性低分子化合物を含む基層を形成するステップと、を有するバルーンカテーテルの製造方法。 - 前記水溶性低分子化合物は、セリンエチルエステル、クエン酸エステル、ポリソルベート、糖、アミノ酸エステル、または短鎖モノカルボン酸のグリセロールエステルの少なくとも1つである請求項13に記載のバルーンカテーテルの製造方法。
- 前記バルーンは、ポリアミド類により形成される請求項13または14に記載のバルーンカテーテルの製造方法。
- 前記基層に含まれる前記水溶性低分子化合物は、結晶、アモルファス、またはこれらの混合物である請求項13〜15のいずれか1項に記載のバルーンカテーテルの製造方法。
- 前記長尺体は、基端部が前記バルーンの平滑で非多孔質の外表面から離れ、かつ前記基層の内部に位置する第1の長尺体、前記バルーンの外表面から延在する第2の長尺体、または前記基層の外表面から面外方向へ延在する第3の長尺体の少なくとも1つを有する請求項13〜16のいずれか1項に記載のバルーンカテーテルの製造方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016058030 | 2016-03-23 | ||
JP2016058030 | 2016-03-23 | ||
PCT/JP2017/011631 WO2017164278A1 (ja) | 2016-03-23 | 2017-03-23 | バルーンカテーテルおよびその製造方法並びに処置方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2017164278A1 JPWO2017164278A1 (ja) | 2018-09-13 |
JP6472572B2 true JP6472572B2 (ja) | 2019-02-20 |
Family
ID=59896292
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018507392A Active JP6472572B2 (ja) | 2016-03-23 | 2017-03-23 | バルーンカテーテルおよびその製造方法並びに処置方法 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11369778B2 (ja) |
EP (1) | EP3391930B1 (ja) |
JP (1) | JP6472572B2 (ja) |
CN (1) | CN108883257B (ja) |
SG (1) | SG11201805457RA (ja) |
WO (1) | WO2017164278A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108883257B (zh) | 2016-03-23 | 2021-05-28 | 泰尔茂株式会社 | 球囊导管及其制造方法以及处置方法 |
JP2017169738A (ja) | 2016-03-23 | 2017-09-28 | テルモ株式会社 | バルーンカテーテルおよびその製造方法並びに処置方法 |
JP6668131B2 (ja) | 2016-03-23 | 2020-03-18 | テルモ株式会社 | バルーンカテーテルおよびその製造方法並びに処置方法 |
CN108057168B (zh) * | 2017-11-08 | 2021-06-29 | 普霖医疗科技(广州)有限公司 | 一种药物球囊的制备方法 |
CN109954198B (zh) * | 2017-12-25 | 2021-10-12 | 先健科技(深圳)有限公司 | 药物球囊及其制备方法 |
CN112546414B (zh) * | 2021-02-22 | 2021-06-08 | 上海微创医疗器械(集团)有限公司 | 载药医疗器械及其制备方法 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002365883A1 (en) * | 2001-11-30 | 2003-06-17 | Bristol-Myers Squibb Company | Paclitaxel solvates |
EP2324866B1 (en) * | 2002-07-12 | 2014-06-18 | Cook Medical Technologies LLC | Angioplasty balloons drug-coated in an expanded condition |
US8241655B2 (en) * | 2004-05-12 | 2012-08-14 | Surmodics, Inc. | Coatings for medical articles including natural biodegradable polysaccharides |
ES2574780T3 (es) | 2005-09-06 | 2016-06-22 | C.R. Bard, Inc. | Injerto de liberación de fármacos |
US20080175887A1 (en) | 2006-11-20 | 2008-07-24 | Lixiao Wang | Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs |
JP5667559B2 (ja) * | 2008-03-28 | 2015-02-12 | サーモディクス,インコーポレイティド | 微粒子が配置された弾性基質を有する挿入可能な医療機器、および薬物送達方法 |
US9198968B2 (en) * | 2008-09-15 | 2015-12-01 | The Spectranetics Corporation | Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens |
ES2550634T3 (es) | 2009-07-10 | 2015-11-11 | Boston Scientific Scimed, Inc. | Uso de nanocristales para un balón de suministro de fármaco |
EP2477617B1 (en) * | 2009-09-18 | 2018-01-31 | Bioinspire Technologies Inc. | Free-standing biodegradable patch |
US8951595B2 (en) * | 2009-12-11 | 2015-02-10 | Abbott Cardiovascular Systems Inc. | Coatings with tunable molecular architecture for drug-coated balloon |
US9168362B2 (en) | 2010-12-21 | 2015-10-27 | Invatec Technology Center Gmbh | Drug eluting balloon for the treatment of stenosis and method of manufacturing the balloon |
WO2012149328A1 (en) | 2011-04-29 | 2012-11-01 | Boston Scientific Scimed, Inc. | Protective surfaces for drug-coated medical devices |
US20130303983A1 (en) * | 2012-05-09 | 2013-11-14 | Cook Medical Technologies Llc | Coated medical devices including a water-insoluble therapeutic agent |
US11167063B2 (en) | 2013-03-14 | 2021-11-09 | W. L. Gore & Associates, Inc. | Porous composites with high-aspect ratio crystals |
US9872940B2 (en) * | 2013-04-01 | 2018-01-23 | Terumo Kabushiki Kaisha | Drug coating layer |
WO2014163093A1 (ja) | 2013-04-01 | 2014-10-09 | テルモ株式会社 | コーティング組成物および医療機器 |
WO2014163092A1 (ja) | 2013-04-01 | 2014-10-09 | テルモ株式会社 | 薬剤コート層、薬剤コート層の形態型を制御する方法および医療機器 |
WO2015103097A1 (en) * | 2014-01-02 | 2015-07-09 | Boston Scientific Scimed, Inc. | Drug eluting balloon with preferred drug orientation to improve drug transfer efficiency |
EP3106198B1 (en) * | 2014-04-01 | 2019-09-18 | Terumo Kabushiki Kaisha | Positioning method for balloon coating |
JP6504571B2 (ja) | 2014-04-01 | 2019-04-24 | テルモ株式会社 | バルーンコーティング方法 |
EP2944331B1 (de) | 2014-05-12 | 2019-10-02 | B. Braun Melsungen AG | Implantierbarer Formkörper |
WO2015175252A1 (en) | 2014-05-16 | 2015-11-19 | Boston Scientific Scimed, Inc. | High pressure low cost multilayer balloon catheter |
WO2015181826A1 (en) | 2014-05-27 | 2015-12-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Crystalline coating and release of bioactive agents |
WO2016118923A1 (en) * | 2015-01-22 | 2016-07-28 | Intersect Ent, Inc. | Drug-coated balloon |
JP2017169738A (ja) | 2016-03-23 | 2017-09-28 | テルモ株式会社 | バルーンカテーテルおよびその製造方法並びに処置方法 |
JP6668131B2 (ja) | 2016-03-23 | 2020-03-18 | テルモ株式会社 | バルーンカテーテルおよびその製造方法並びに処置方法 |
CN108883257B (zh) | 2016-03-23 | 2021-05-28 | 泰尔茂株式会社 | 球囊导管及其制造方法以及处置方法 |
-
2017
- 2017-03-23 CN CN201780019565.6A patent/CN108883257B/zh active Active
- 2017-03-23 EP EP17770318.8A patent/EP3391930B1/en active Active
- 2017-03-23 WO PCT/JP2017/011631 patent/WO2017164278A1/ja active Application Filing
- 2017-03-23 JP JP2018507392A patent/JP6472572B2/ja active Active
- 2017-03-23 SG SG11201805457RA patent/SG11201805457RA/en unknown
- 2017-03-23 US US15/467,304 patent/US11369778B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US11369778B2 (en) | 2022-06-28 |
EP3391930A4 (en) | 2019-09-11 |
JPWO2017164278A1 (ja) | 2018-09-13 |
EP3391930B1 (en) | 2024-06-05 |
US20170274187A1 (en) | 2017-09-28 |
SG11201805457RA (en) | 2018-10-30 |
CN108883257A (zh) | 2018-11-23 |
CN108883257B (zh) | 2021-05-28 |
WO2017164278A1 (ja) | 2017-09-28 |
EP3391930A1 (en) | 2018-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6472572B2 (ja) | バルーンカテーテルおよびその製造方法並びに処置方法 | |
JPWO2015151877A1 (ja) | バルーンコーティング方法、コート層制御方法およびバルーンコーティング装置 | |
JPWO2015151879A1 (ja) | バルーンコーティングのための位置決め方法 | |
JP6754423B2 (ja) | バルーンカテーテル及びその製造方法 | |
WO2017164281A1 (ja) | バルーンカテーテル及びその製造方法並びに処置方法 | |
JP2017169740A (ja) | バルーンカテーテルおよびその製造方法並びに処置方法 | |
US11369777B2 (en) | Balloon catheter and manufacturing method thereof, and treatment method | |
JP7073337B2 (ja) | バルーンカテーテルの製造方法 | |
US11369776B2 (en) | Balloon catheter and manufacturing method thereof, and treatment method | |
JP2018153291A (ja) | バルーンカテーテルの製造方法および製造装置 | |
JP2018153290A (ja) | バルーンカテーテルの製造方法および製造装置 | |
JP7073339B2 (ja) | バルーンカテーテルおよびその製造方法 | |
WO2018169051A1 (ja) | バルーンコーティング方法 | |
JP6723779B2 (ja) | バルーンカテーテルおよび処置方法 | |
JP6914612B2 (ja) | バルーンカテーテル及びその製造方法並びに処置方法 | |
JP2018153289A (ja) | バルーンカテーテルの製造方法および製造装置 | |
JP2017169737A (ja) | バルーンカテーテル及びその製造方法並びに処置方法 | |
WO2017164279A1 (ja) | バルーンカテーテルおよびその製造方法並びに処置方法 | |
WO2017164282A1 (ja) | バルーンカテーテルおよびその製造方法並びに処置方法 | |
JP2017169742A (ja) | バルーンカテーテルおよびその製造方法並びに処置方法 | |
JP2018153282A (ja) | バルーンコーティング方法 | |
JP2017169733A (ja) | バルーンカテーテルおよびその製造方法並びに処置方法 | |
JP2017169735A (ja) | バルーンカテーテル及びその製造方法並びに処置方法 | |
JP2018153285A (ja) | バルーンコーティング方法 | |
JP2017169736A (ja) | バルーンカテーテル及びその製造方法並びに処置方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180501 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20180501 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20180529 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180604 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180723 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180926 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181002 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181129 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181225 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190122 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6472572 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |